Is there a role for PD-1 inhibitors for metastatic or locally recurrent cutaneous squamous cell carcinomas after failure of first line therapy, EGFR inhibitors?

Is it commonly used if no clinical trials are available?

Answer from: Medical Oncologist at Academic Institution

Yes. response rate close to 50%. Look at ASCO abstract from 2017 phase 1 looking at new PD-1 inhibitor in treat this disease